Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

Science

Volumn 319, Issue 5869, 2008, Pages 1536-1539

  George, David T ^a   Gilman, Jodi ^a   Hersh, Jacqueline ^a   Thorsell, Annika ^a   Herion, David ^a   Geyer, Christopher ^b   Peng, Xiaomei ^c   Kielbasa, William ^c   Rawlings, Robert ^a   Brandt, John E ^c   Gehlert, Donald R ^c   Tauscher, Johannes T ^c   Hunt, Stephen P ^d   Hommer, Daniel ^a   Heilig, Markus ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROPHENYL [2 [5 PYRIDIN 4 YL 1 (3,5 BISTRIFLUOROMETHYLBENZYL) 1H [1,2,3]TRIAZOL 4 YL]PYRIDIN 3 YL]METHANONE; ALCOHOL; HYDROCORTISONE; LY 686017; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG;

ALCOHOL; BEHAVIORAL RESPONSE; BRAIN; EXPERIMENTAL STUDY; HORMONE; PEPTIDE; PUBLIC HEALTH;

ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HORMONE RESPONSE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEDATION; STIMULUS RESPONSE; STRESS; WELLBEING; WITHDRAWAL SYNDROME;

ADULT; AGED; ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; EMOTIONS; ETHANOL; FEMALE; HUMANS; HYDROCORTISONE; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PYRIDINES; RECEPTORS, NEUROKININ-1; TRIAZOLES;

MUS;

EID: 40849106521     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1153813     Document Type: Article

References (28)

1. M. Ezzati, A. D. Lopez, A. Rodgers, S. van den Horn, C. J. Murray, Lancet 360, 1347 (2002).
2. K. D. Brownell, G. A. Marlatt, E. Lichtenstein, G. T. Wilson, Am. Psychol. 41, 765 (1986).
3. A. D. Lê et al., Psychopharmacology (Berlin) 135, 169 (1998).
4. M. Heilig, M. Egli, Pharmacol. Ther. 111, 855 (2006).
5. X. Liu, F. Weiss, J. Neurosci. 22, 7856 (2002).
6. R. Sinha, C. S. Li, Drug Alcohol Rev. 26, 25 (2007).
7. M. Heilig, G. F. Koob, Trends Neurosci. 30, 399 (2007).
8. A. Holmes, M. Heilig, N. M. J. Rupniak, T. Steckler, G. Griebel, Trends Pharmacol. Sci. 24, 580 (2003).
9. T. L. Ripley, C. A. Gadd, C. De Felipe, S. P. Hunt, D. N. Stephens, Neuropharmacology 43, 1258 (2002).
10. P. Murtra, A. M. Sheasby, S. P. Hunt, F. C. De, Nature 405, 180 (2000).
11. T. Furmark et al., Biol. Psychiatry 58, 132 (2005).
12. Materials and methods are available as supporting material on Science Online.
13. C. De Felipe et al., Nature 392, 394 (1998).
14. J. C. Crabbe, T. J. Phillips, Psychopharmacology (Berlin) 174, 539 (2004).
15. M. A. Schuckit, T. L. Smith, J. Kalmijn, Alcohol. Clin. Exp. Res. 28, 1449 (2004).
16. A. K. Amegadzie et al., "Preparation of triazole derivatives as tachykinin receptor antagonists." (WO 2003091226 A1, World Intellectual Property Organization); published online 6 November 2003, www.wipo.int/pctdb/en/ wo.jsp?wo=2003091226.
17. C. D. Spielberger, R. L. Gorsuch, R. E. Lushene, Manual for the State-Trait Anxiety Inventory (Consulting Psychologist Press, Palo Alto, CA, 1970).
18. P. J. Lang, M. M. Bradley, B. N. Cuthbert, International Affective Picture System (IAPS): Technical Manual and Affective Ratings (The Center for Research in Psychophysiology, Univ. of Florida, Gainesville, FL, 1995).
19. J. M. Gilman, D. Hommer, Addiction Biol., in press.
20. A. L. Brody et al., Arch. Gen. Psychiatry 59, 1162 (2002).
21. N. H. Naqvi, D. Rudrauf, H. Damasio, A. Bechara, Science 315, 531 (2007).
22. A. Heinz et al., Alcohol. Clin. Exp. Res. 31, 1138 (2007).
23. B. A. Flannery, S. A. Poole, R. J. Gallop, J. R. Volpicelli, J. Stud. Alcohol 64, 120 (2003).
24. S. S. O'Malley, S. Krishnan-Sarin, C. Farren, R. Sinha, M. J. Kreek, Psychopharmacology (Berlin) 160, 19 (2002).
25. S. T. Tiffany, Psychol. Rev. 97, 147 (1990).
26. M. S. Kramer et al., Science 281, 1640 (1998).
27. J. M. Lundberg, T. Hökfelt, Trends Neurosci. 6, 325 (1983).
28. We thank nurse manager J. Johnson and her treatment staff at the 1SE Unit of the NIH Clinical Center, as well as D. Hill, L. Doty, and C. Jones for their invaluable contributions to this study. R. Anton, S. Thomas, R. Miranda, and P. Monti are gratefully acknowledged for input in the design stages of the clinical study. Supported by the intramural research budget of the National Institute on Alcohol Abuse and Alcoholism, NIH. This work was carried out under a Collaborative Research and Development Agreement (CRADA) between the U.S. Government and Eli Lilly and Co. All coauthors so indicated are employees of Eli Lilly and Co.; the remaining authors have no conflict of interest to disclose.